Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapSuper Stock

REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical CO LTD





 




RNS Number : 0700I
Societe Generale SA
21 November 2018
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION     

 

(a) Full name of discloser:

Société Générale S.A.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

 

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Takeda Pharmaceutical CO LTD

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:


(e) Date position held/dealing undertaken:

     For an opening position disclosure, state the latest practicable date prior to the disclosure

20/11/2018       

(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

     If it is a cash offer or possible cash offer, state "N/A"

YES: Shire PLC

 

 

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary

 

 

Interests

Short positions


Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,940,819

0.25

8,703,260

1.11

(2) Cash-settled derivatives:

 

7,818,633

1.00

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

121,500

0.02

125,000

0.02

 

     TOTAL:

9,880,952

1.26

8,828,260

1.13

           

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)        Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:


Details, including nature of the rights concerned and relevant percentages:


 

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

JPY

Ordinary

Purchase

200

4423

Ordinary

Purchase

100

4454

Ordinary

Purchase

200

4412

Ordinary

Purchase

200

4393

Ordinary

Purchase

200

4419

Ordinary

Purchase

200

4452

Ordinary

Purchase

100

4419

Ordinary

Purchase

100

4419

Ordinary

Purchase

200

4435

Ordinary

Purchase

200

4434

Ordinary

Purchase

200

4393

Ordinary

Purchase

2,000

4441

Ordinary

Purchase

1,400

4475

Ordinary

Purchase

4,200

4425

Ordinary

Purchase

700

4423

Ordinary

Purchase

1,200

4400

Ordinary

Purchase

2,500

4414

Ordinary

Purchase

300

4442

Ordinary

Purchase

2,200

4440

Ordinary

Purchase

1,900

4426

Ordinary

Purchase

1,400

4461

Ordinary

Purchase

500

4464

Ordinary

Purchase

1,400

4465

Ordinary

Purchase

100

4370

Ordinary

Purchase

100

4371

Ordinary

Purchase

100

4374

Ordinary

Purchase

1,800

4379

Ordinary

Purchase

800

4427

Ordinary

Purchase

100

4434

Ordinary

Purchase

2,500

4424

Ordinary

Purchase

300

4399

Ordinary

Purchase

300

4414

Ordinary

Purchase

2,600

4476

Ordinary

Purchase

100

4443

Ordinary

Purchase

200

4425

Ordinary

Purchase

100

4378

Ordinary

Purchase

600

4386

Ordinary

Purchase

1,800

4370

Ordinary

Purchase

400

4476

Ordinary

Purchase

100

4406

Ordinary

Purchase

100

4406

Ordinary

Purchase

200

4390

Ordinary

Purchase

100

4408.5

Ordinary

Purchase

500

4387

Ordinary

Purchase

300

4391

Ordinary

Purchase

300

4389

Ordinary

Purchase

700

4399

Ordinary

Purchase

100

4400

Ordinary

Purchase

1,100

4393

Ordinary

Purchase

1,100

4403

Ordinary

Purchase

1,100

4403

Ordinary

Purchase

600

4407

Ordinary

Purchase

400

4407

Ordinary

Purchase

200

4402

Ordinary

Purchase

1,100

4414

Ordinary

Purchase

1,000

4419

Ordinary

Purchase

700

4418

Ordinary

Purchase

1,100

4420

Ordinary

Purchase

200

4407

Ordinary

Purchase

100

4405

Ordinary

Purchase

100

4405

Ordinary

Purchase

200

4406

Ordinary

Purchase

300

4400

Ordinary

Purchase

800

4404

Ordinary

Purchase

1,100

4410

Ordinary

Purchase

500

4423

Ordinary

Purchase

1,100

4420

Ordinary

Purchase

200

4375

Ordinary

Purchase

300

4372

Ordinary

Purchase

1,100

4373

Ordinary

Purchase

100

4375

Ordinary

Purchase

500

4380

Ordinary

Purchase

100

4382

Ordinary

Purchase

200

4428

Ordinary

Purchase

100

4393

Ordinary

Purchase

100

4393

Ordinary

Purchase

100

4390

Ordinary

Purchase

400

4396

Ordinary

Purchase

200

4391

Ordinary

Purchase

600

4397

Ordinary

Purchase

600

4398

Ordinary

Purchase

100

4410

Ordinary

Purchase

200

4409

Ordinary

Purchase

1,100

4410

Ordinary

Purchase

400

4390

Ordinary

Purchase

5,600

4476

Ordinary

Sale

1,200

4404

Ordinary

Sale

100

4427

Ordinary

Sale

200

4419

Ordinary

Sale

200

4418

Ordinary

Sale

1,000

4407

Ordinary

Sale

500

4409

Ordinary

Sale

100

4411

Ordinary

Sale

500

4412

Ordinary

Sale

100

4417

Ordinary

Sale

300

4414

Ordinary

Sale

1,300

4413

Ordinary

Sale

500

4412

Ordinary

Sale

100

4415

Ordinary

Sale

100

4418

Ordinary

Sale

300

4400

Ordinary

Sale

100

4419

Ordinary

Sale

1,100

4420

Ordinary

Sale

100

4419

Ordinary

Sale

800

4421

Ordinary

Sale

800

4421

Ordinary

Sale

100

4409

Ordinary

Sale

800

4405

Ordinary

Sale

200

4408

Ordinary

Sale

600

4406

Ordinary

Sale

400

4406

Ordinary

Sale

200

4410

Ordinary

Sale

700

4410

Ordinary

Sale

600

4409

Ordinary

Sale

100

4415

Ordinary

Sale

1,000

4403

Ordinary

Sale

100

4401

Ordinary

Sale

900

4390

Ordinary

Sale

1,500

4414

Ordinary

Sale

100

4394

Ordinary

Sale

100

4391

Ordinary

Sale

200

4389

Ordinary

Sale

100

4464

Ordinary

Sale

10,000

4400

Ordinary

Sale

10,000

4397

Ordinary

Sale

10,000

4410

Ordinary

Sale

5,000

4420

Ordinary

Sale

5,000

4435

Ordinary

Sale

5,000

4445

Ordinary

Sale

100

4419.5

Ordinary

Sale

100

4408.5

Ordinary

Sale

5,400

4417.630322

Ordinary

Sale

1,100

4421

Ordinary

Sale

100

4419

Ordinary

Sale

100

4415

Ordinary

Sale

100

4406

Ordinary

Sale

200

4424

Ordinary

Sale

400

4396

Ordinary

Sale

600

4386

Ordinary

Sale

600

4395

Ordinary

Sale

600

4391

Ordinary

Sale

100

4426.5

Ordinary

Sale

600

4426.5

Ordinary

Sale

400

4426.5

Ordinary

Sale

700

4427

Ordinary

Sale

100

4434

Ordinary

Sale

100

4434

Ordinary

Sale

100

4434

Ordinary

Sale

400

4459.5

Ordinary

Sale

500

4459.5

Ordinary

Sale

200

4421

Ordinary

Sale

900

4419

Ordinary

Sale

400

4417.5

Ordinary

Sale

1,400

4465

Ordinary

Sale

100

4392

Ordinary

Sale

100

4390

Ordinary

Sale

100

4438

Ordinary

Sale

100

4407

Ordinary

Sale

100

4406

Ordinary

Sale

100

4402

Ordinary

Sale

100

4409

Ordinary

Sale

100

4410

Ordinary

Sale

100

4410

Ordinary

Sale

100

4407

Ordinary

Sale

100

4406

Ordinary

Sale

100

4414

Ordinary

Sale

100

4416

Ordinary

Sale

100

4413

Ordinary

Sale

100

4417

Ordinary

Sale

100

4419

Ordinary

Sale

100

4414

Ordinary

Sale

100

4405

Ordinary

Sale

100

4406

Ordinary

Sale

100

4405

Ordinary

Sale

100

4413

Ordinary

Sale

100

4406

Ordinary

Sale

100

4416

Ordinary

Sale

1,000

4370

Ordinary

Sale

1,100

4370

Ordinary

Sale

100

4393

Ordinary

Sale

100

4396

Ordinary

Sale

100

4391

Ordinary

Sale

100

4393

Ordinary

Sale

100

4443

Ordinary

Sale

1,100

4444

Ordinary

Sale

1,100

4424

Ordinary

Sale

200

4436

Ordinary

Sale

1,100

4425

Ordinary

Sale

600

4436

Ordinary

Sale

300

4426

Ordinary

Sale

200

4425

Ordinary

Sale

700

4455

Ordinary

Sale

1,100

4427

Ordinary

Sale

300

4429

Ordinary

Sale

500

4442

Ordinary

Sale

100

4421

Ordinary

Sale

1,100

4459

Ordinary

Sale

100

4420

Ordinary

Sale

100

4417

Ordinary

Sale

1,100

4464

Ordinary

Sale

700

4451

Ordinary

Sale

200

4430

Ordinary

Sale

200

4419

Ordinary

Sale

620

3957.3

Ordinary

Sale

5,600

4476


Total Purchases

60,700



Total Sales

99,320


 

 

(b)        Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit JPY

Ordinary

CFD

 Increasing a long position

31,700

4 406.173418

Ordinary

CFD

 Increasing a long position

18,300

4 406.173418

 

 (c)       Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit JPY









 

(ii)        Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit JPY





 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable) JPY


 

 



4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c)        Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

 

 

Date of disclosure:

21/11/2018

Contact name:

Olivier Vero

Telephone number:

+44 20 7676 6969

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk             



SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

 

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

 

1.         KEY INFORMATION

 

Full name of person making disclosure:

SOCIETE GENERALE SA

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

Takeda Pharmaceutical CO LTD

 

2.         STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

 

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

Expiry date

JPY

e.g. American, European etc.

Ordinary

OTC put-option

Sale

15,700

4707

European options

14/12/2018

Ordinary

OTC put-option

Sale

30,000

5075.10

European options

14/12/2018

Ordinary

OTC put-option

Sale

29,600

5073.65

European options

14/12/2018

Ordinary

OTC put-option

Sale

15,500

4491.40

European options

14/12/2018

Ordinary

OTC put-option

Sale

30,700

4533.90

European options

14/12/2018

Ordinary

Listed call-option

Sale

125,000

5500

European options

13/06/2019

 

 

 

3.         AGREEMENTS TO PURCHASE OR SELL ETC.

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

 

 

 

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

 

The currency of all prices and other monetary amounts should be stated.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETPGGUAGUPRUBG

Recent news on Takeda Pharmaceutical Co

See all news